Research programme: small molecule therapeutics - VistaGen

Drug Profile

Research programme: small molecule therapeutics - VistaGen

Alternative Names: Drug rescue variants - VistaGen

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VistaGen Therapeutics
  • Developer Synterys; VistaGen Therapeutics
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA
  • 23 Apr 2014 VistaGen licenses patents entitled Mesoderm and Definitive Endoderm Cell Populations from Icahn School of Medicine
  • 14 Feb 2012 VistaGen has identified its initial top ten drug rescue candidates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top